The current state of GPCR-based drug discovery to treat metabolic disease

British Journal of Pharmacology

Volumn 175, Issue 21, 2018, Pages 4060-4071

  Sloop, Kyle W ^a   Emmerson, Paul J ^a   Statnick, Michael A ^a   Willard, Francis S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIGAND;

CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; FEASIBILITY STUDY; HEALTH CARE QUALITY; HUMAN; METABOLIC DISORDER; MOLECULAR INTERACTION; NOMENCLATURE; NONHUMAN; OBESITY; PATENT; PRECLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; TRANSLATIONAL RESEARCH; VALIDATION PROCESS; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECT; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; DRUG DISCOVERY; HUMANS; METABOLIC DISEASES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85044433297     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.14157     Document Type: Review

References (74)

1. Ahren B (2007). Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 30: 1344–1350.
2. Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA et al. (2017a). The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol 174 (Suppl 1): S17–S129.
3. Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E et al. (2017b). The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol 174: S272–S359.
4. Alexander SPH, Cidlowski JA, Kelly E, Marrion NV, Peters JA, Faccenda E et al. (2017c). The Concise Guide to PHARMACOLOGY 2017/18: Nuclear hormone receptors. Br J Pharmacol 174: S208–S224.
5. Alexander SPH, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD et al. (2017d). The Concise Guide to PHARMACOLOGY 2017/18: Transporters. Br J Pharmacol 174: S360–S446.
6. Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA et al. (2003). Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52: 947–952.
7. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL et al. (2002). Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650–654.
8. Berglund ED, Vianna CR, Donato J Jr, Kim MH, Chuang JC, Lee CE et al. (2012). Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin Invest 122: 1000–1009.
9. Chen KY, Muniyappa R, Abel BS, Mullins KP, Staker P, Brychta RJ et al. (2015). RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocrinol Metab 100: 1639–1645.
10. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63: PL113–PL117.
11. DeFronzo RA, Tripathy D (2009). Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32 (Suppl 2): S157–S163.
12. Dobbins R, Byerly R, Gaddy R, Gao F, Mahar K, Napolitano A et al. (2015). GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial. Eur J Pharmacol 755: 95–101.
13. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS (2014). Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13: 885–892.
14. Drucker DJ (2006). The biology of incretin hormones. Cell Metab 3: 153–165.
15. Drucker DJ (2016). The cardiovascular biology of glucagon-like peptide-1. Cell Metab 24: 15–30.
16. Duan H, Ning M, Zou Q, Ye Y, Feng Y, Zhang L et al. (2015). Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes. J Med Chem 58: 3315–3328.
17. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267: 7402–7405.
18. Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C et al. (2006). Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 4: 275–282.
19. Farb TB, Adeva M, Beauchamp TJ, Cabrera O, Coates DA, DeShea Meredith T et al. (2017). Regulation of endogenous (male) rodent GLP-1 secretion and human islet insulin secretion by antagonism of somatostatin receptor 5. Endocrinology 158: 3859–3873.
20. Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM et al. (2013). Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5: 209ra151.
21. Fisher SL, Yagaloff KA, Burn P (1999). Melanocortin-4 receptor: a novel signalling pathway involved in body weight regulation. Int J Obes Relat Metab Disord 23 (Suppl 1): 54–58.
22. Gorski JN, Pachanski MJ, Mane J, Plummer CW, Souza S, Thomas-Fowlkes BS et al. (2017). GPR40 reduces food intake and body weight through GLP-1. Am J Physiol Endocrinol Metab 313: E37–E47.
23. Graaf C, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ et al. (2016). Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev 68: 954–1013.
24. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K et al. (2009). Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17: 30–39.
25. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K et al. (2004). Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53: 1326–1335.
26. Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res 46 (D1): D1091–D1106.
27. Harris KB, McCarty DJ (2015). Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 6: 3–18.
28. Hauge M, Ekberg JP, Engelstoft MS, Timshel P, Madsen AN, Schwartz TW (2016). Gq and Gs signaling acting in synergy to control GLP-1 secretion. Mol Cell Endocrinol 449: 64–73.
29. Hodge RJ, Lin J, Vasist Johnson LS, Gould EP, Bowers GD, Nunez DJ (2013). Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes. Clin Pharmacol Drug Dev 2: 213–222.
30. Hsiao WC, Shia KS, Wang YT, Yeh YN, Chang CP, Lin Y et al. (2015). A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis. Diabetes Obes Metab 17 (5): 495–504.
31. Ito M, Grujic D, Abel ED, Vidal-Puig A, Susulic VS, Lawitts J et al. (1998). Mice expressing human but not murine beta3-adrenergic receptors under the control of human gene regulatory elements. Diabetes 47: 1464–1471.
32. Jelinek LJ, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S et al. (1993). Expression cloning and signaling properties of the rat glucagon receptor. Science 259: 1614–1616.
33. Jensen AA, Brauner-Osborne H (2007). Allosteric modulation of the calcium-sensing receptor. Curr Neuropharmacol 5: 180–186.
34. Jordan J, Greenway FL, Leiter LA, Li Z, Jacobson P, Murphy K et al. (2008). Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 83: 281–287.
35. Jorgensen NB, Dirksen C, Bojsen-Moller KN, Jacobsen SH, Worm D, Hansen DL et al. (2013). Exaggerated glucagon-like peptide 1 response is important for improved beta-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62: 3044–3052.
36. Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R (2015). Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 17: 675–681.
37. Kang SU (2013). GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119. Drug Discov Today 18: 1309–1315.
38. Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, Xi L et al. (2012). Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab 14: 709–716.
39. Krishna R, Gumbiner B, Stevens C, Musser B, Mallick M, Suryawanshi S et al. (2009). Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 86: 659–666.
40. Kuhnen P, Clement K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL et al. (2016). Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med 375: 240–246.
41. Lafontan M, Piazza PV, Girard J (2007). Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab 33: 85–95.
42. Lan H, Hoos LM, Liu L, Tetzloff G, Hu W, Abbondanzo SJ et al. (2008). Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 57: 2999–3006.
43. Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A et al. (2009). GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 201: 219–230.
44. Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH et al. (2002). Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr 76: 780–788.
45. Lefkowitz RJ (2007). Seven transmembrane receptors: something old, something new. Acta Physiol (Oxf) 190: 9–19.
46. Li T, Holmstrom SR, Kir S, Umetani M, Schmidt DR, Kliewer SA et al. (2011). The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 25: 1066–1071.
47. Lowell BB, Bachman ES (2003). β-Adrenergic receptors, diet-induced thermogenesis, and obesity. J Biol Chem 278: 29385–29388.
48. Luo J, Swaminath G, Brown SP, Zhang J, Guo Q, Chen M et al. (2012). A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PloS one 7: e46300.
49. Mancini AD, Poitout V (2015). GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit. Diabetes Obes Metab 17: 622–629.
50. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375: 1834–1844.
51. Mietlicki-Baase EG (2016). Amylin-mediated control of glycemia, energy balance, and cognition. Physiol Behav 162: 130–140.
52. Motani AS, Luo J, Liang L, Mihalic JT, Chen X, Tang L et al. (2013). Evaluation of AMG 076, a potent and selective MCHR1 antagonist, in rodent and primate obesity models. Pharmacol Res Perspect 1: e00003.
53. Muller TD, Finan B, Clemmensen C, DiMarchi RD, Tschop MH (2017). The new biology and pharmacology of glucagon. Physiol Rev 97: 721–766.
54. Nunez DJ, Bush MA, Collins DA, McMullen SL, Gillmor D, Apseloff G et al. (2014). Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. PloS one 9: e92494.
55. Oh DY, Walenta E, Akiyama TE, Lagakos WS, Lackey D, Pessentheiner AR et al. (2014). A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med 20: 942–947.
56. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR et al. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9: 203–214.
57. Pearson MJ, Unger RH, Holland WL (2016). Clinical trials, triumphs, and tribulations of glucagon receptor antagonists. Diabetes Care 39: 1075–1077.
58. Provensi G, Blandina P, Passani MB (2016). The histaminergic system as a target for the prevention of obesity and metabolic syndrome. Neuropharmacology 106: 3–12.
59. Ritter K, Buning C, Halland N, Poverlein C, Schwink L (2016). G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges. J Med Chem 59: 3579–3592.
60. Rodbell M (1973). The problem of identifying the glucagon receptor. Fed Proc 32: 1854–1858.
61. Roth BL, Kroeze WK (2015). Integrated approaches for genome-wide interrogation of the druggable non-olfactory G protein-coupled receptor superfamily. J Biol Chem 290: 19471–19477.
62. Sadek B, Stark H (2016). Cherry-picked ligands at histamine receptor subtypes. Neuropharmacology 106: 56–73.
63. Samuel VT, Shulman GI (2016). The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 126: 12–22.
64. Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG et al. (2017). A comprehensive map of molecular drug targets. Nat Rev Drug Discov 16: 19–34.
65. Satapati S, Qian Y, Wu MS, Petrov A, Dai G, Wang SP et al. (2017). GPR120 suppresses adipose tissue lipolysis and synergizes with GPR40 in antidiabetic efficacy. J Lipid Res 58: 1561–1578.
66. Schwartz MW, Seeley RJ, Tschop MH, Woods SC, Morton GJ, Myers MG et al. (2013). Cooperation between brain and islet in glucose homeostasis and diabetes. Nature 503: 59–66.
67. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R et al. (2015). New genetic loci link adipose and insulin biology to body fat distribution. Nature 518: 187–196.
68. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL et al. (2004). Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113: 1571–1581.
69. Susulic VS, Frederich RC, Lawitts J, Tozzo E, Kahn BB, Harper ME et al. (1995). Targeted disruption of the beta 3-adrenergic receptor gene. J Biol Chem 270: 29483–29492.
70. Tao YX (2009). Mutations in melanocortin-4 receptor and human obesity. Prog Mol Biol Transl Sci 88: 173–204.
71. Walston J, Silver K, Bogardus C, Knowler WC, Celi FS, Austin S et al. (1995). Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 333: 343–347.
72. Weintraub M, Sundaresan PR, Madan M, Schuster B, Balder A, Lasagna L et al. (1992). Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 51: 586–594.
73. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P (2012). The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther 340: 483–489.
74. Zimmet PZ, Magliano DJ, Herman WH, Shaw JE (2014). Diabetes: a 21st century challenge. The Lancet Diabetes & endocrinology 2: 56–64.